Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $38.60 $44.37 Friday, 10th May 2024 XENE stock ended at $40.54. This is 4.59% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 10.26% from a day low at $38.60 to a day high of $42.56.
90 days $38.60 $50.99
52 weeks $27.99 $50.99

Historical Xenon Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Apr 05, 2024 $42.04 $42.78 $41.48 $42.25 177 053
Apr 04, 2024 $41.50 $42.68 $41.36 $42.21 272 880
Apr 03, 2024 $41.47 $41.75 $40.97 $41.30 242 746
Apr 02, 2024 $41.85 $42.01 $41.14 $41.47 229 980
Apr 01, 2024 $43.18 $43.18 $41.26 $42.14 233 884
Mar 28, 2024 $42.88 $43.55 $42.38 $43.05 307 762
Mar 27, 2024 $42.76 $43.19 $42.08 $43.00 433 170
Mar 26, 2024 $43.00 $43.52 $42.59 $42.66 181 822
Mar 25, 2024 $43.97 $44.47 $42.51 $42.70 398 787
Mar 22, 2024 $43.66 $44.15 $43.20 $44.00 263 744
Mar 21, 2024 $44.11 $44.81 $43.44 $43.45 301 481
Mar 20, 2024 $44.05 $44.05 $43.02 $43.79 184 172
Mar 19, 2024 $42.89 $44.51 $42.24 $44.35 435 518
Mar 18, 2024 $43.83 $44.37 $42.82 $42.89 328 562
Mar 15, 2024 $43.71 $44.46 $43.34 $43.96 249 741
Mar 14, 2024 $44.90 $45.03 $43.10 $43.67 281 447
Mar 13, 2024 $44.40 $45.16 $44.08 $45.08 261 913
Mar 12, 2024 $44.30 $45.47 $43.91 $44.25 449 485
Mar 11, 2024 $45.70 $45.70 $44.03 $44.37 600 330
Mar 08, 2024 $46.23 $46.87 $45.49 $46.24 257 640
Mar 07, 2024 $46.03 $46.69 $45.65 $46.16 248 558
Mar 06, 2024 $46.00 $47.44 $45.57 $45.96 353 150
Mar 05, 2024 $46.07 $46.75 $45.36 $46.00 251 323
Mar 04, 2024 $47.80 $47.80 $44.81 $45.95 442 548
Mar 01, 2024 $49.51 $50.99 $46.70 $46.84 718 268
Click to get the best stock tips daily for free!

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o... XENE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT